John Gray
Well-Known Member
- Relationship to Diabetes
- Type 2
I've just received a notification from my doctor as above, linking to a 12-page Sheffield Teaching Hospital leaflet on the subject issued in June 2022 (attached as pil5170_1_.pdf below).
"Why have I been given this leaflet?
You have been given this leaflet because you are taking, or about to take, one of tablets in the list below:
• Empagliflozin (Jardiance®)
• Canagliflozin (Invokana®)
• Dapagliflozin (Forxiga®)
• Ertugliflozin (Steglatro®)
These tablets are called Sodium-glucose co-transporter-2 inhibitors or SGLT2 inhibitors."
The "Rare Side-Effects' (1 in 1,000 to 1 in 10,000 people that take the medication) to which the doctor referred appear to be:
• Necrotising fasciitis of the perineum (Fournier’s gangrene)
• Diabetic ketoacidosis (DKA)
I'm not sure why the sudden fuss/warning - can anyone elucidate?
"Why have I been given this leaflet?
You have been given this leaflet because you are taking, or about to take, one of tablets in the list below:
• Empagliflozin (Jardiance®)
• Canagliflozin (Invokana®)
• Dapagliflozin (Forxiga®)
• Ertugliflozin (Steglatro®)
These tablets are called Sodium-glucose co-transporter-2 inhibitors or SGLT2 inhibitors."
The "Rare Side-Effects' (1 in 1,000 to 1 in 10,000 people that take the medication) to which the doctor referred appear to be:
• Necrotising fasciitis of the perineum (Fournier’s gangrene)
• Diabetic ketoacidosis (DKA)
I'm not sure why the sudden fuss/warning - can anyone elucidate?